KTN0182A, an Anti-KIT, Pyrrolobenzodiazepine (PBD)-Containing Antibody Drug Conjugate (ADC) Demonstrates Potent Antitumor Activity In Vitro and In Vivo Against a Broad Range of Tumor Types

摘要

KIT (CD 117), a type III receptor tyrosine kinase and receptor for the Stem Cell Factor (SCF) ligand, has been implicated in numerous human malignancies, including small cell lung cancer (SCLC), melanoma, acute myeloid leukemia (AML), sarcoma and gastrointestinal stromal tumors (GIST). Targeting of oncogenic mutant KIT by small molecules such as imatinib and sunitinib has proven successful, however acquired resistance is often limiting.